Glucagonoma risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(Mahshid) |
||
| (18 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Glucagonoma}} | {{Glucagonoma}} | ||
{{CMG}}{{AE}}{{PSD}} | {{CMG}}; {{AE}} {{PSD}}, {{MAD}} | ||
==Overview== | ==Overview== | ||
The most common risk factor in the development of glucagonoma is a positive family history of [[multiple endocrine neoplasia type 1|multiple endocrine neoplasia type1]] which is characterized by the presence of [[Pituitary adenoma|pituitary adenomas]], [[Islet cell tumor|islet cell tumors]] of the [[pancreas]], and [[hyperparathyroidism]]. | |||
==Risk Factors== | ==Risk Factors== | ||
* The most common risk factor in the development of glucagonoma is a positive family history of [[multiple endocrine neoplasia type 1]].<ref name="pmid22970401">{{cite journal| author=Afsharfard A, Atqiaee K, Lotfollahzadeh S, Alborzi M, Derakhshanfar A| title=Necrolytic migratory erythema as the first manifestation of glucagonoma. | journal=Case Rep Surg | year= 2012 | volume= 2012 | issue= | pages= 974210 | pmid=22970401 | doi=10.1155/2012/974210 | pmc=PMC3434377 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22970401 }} </ref><ref name="causes">Glucagonoma. U.S. National Library of Medicine. https://www.nlm.nih.gov/medlineplus/ency/article/000326.htm</ref> | |||
** It is an [[Autosomal dominant inheritance|autosomal dominant]] syndrome that is usually caused by mutations in the [[MEN1 syndrome|''MEN1'' gene]]. | |||
** It is characterized by the development of the following tumors:<sup>[[Multiple endocrine neoplasia type 1 pathophysiology#cite note-wikipedia-1|[1]]]</sup> | |||
*** [[Pituitary adenoma|Pituitary adenomas]] | |||
*** [[Islet cell tumor|Islet cell tumors]] of the [[pancreas]] (commonly [[gastrinoma]] and glucagonoma) | |||
*** [[Parathyroid]] [[hyperplasia]] with resulting [[hyperparathyroidism]] | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category: | [[Category:Medicine]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 01:49, 27 November 2017
|
Glucagonoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glucagonoma risk factors On the Web |
|
American Roentgen Ray Society Images of Glucagonoma risk factors |
|
Risk calculators and risk factors for Glucagonoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2], Mohammed Abdelwahed M.D[3]
Overview
The most common risk factor in the development of glucagonoma is a positive family history of multiple endocrine neoplasia type1 which is characterized by the presence of pituitary adenomas, islet cell tumors of the pancreas, and hyperparathyroidism.
Risk Factors
- The most common risk factor in the development of glucagonoma is a positive family history of multiple endocrine neoplasia type 1.[1][2]
- It is an autosomal dominant syndrome that is usually caused by mutations in the MEN1 gene.
- It is characterized by the development of the following tumors:[1]
- Pituitary adenomas
- Islet cell tumors of the pancreas (commonly gastrinoma and glucagonoma)
- Parathyroid hyperplasia with resulting hyperparathyroidism
References
- ↑ Afsharfard A, Atqiaee K, Lotfollahzadeh S, Alborzi M, Derakhshanfar A (2012). "Necrolytic migratory erythema as the first manifestation of glucagonoma". Case Rep Surg. 2012: 974210. doi:10.1155/2012/974210. PMC 3434377. PMID 22970401.
- ↑ Glucagonoma. U.S. National Library of Medicine. https://www.nlm.nih.gov/medlineplus/ency/article/000326.htm